Business Description
Protagenic Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US74365N3017
Total Employee Number:
4Description
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.55 | |||||
Equity-to-Asset | -0.54 | |||||
Debt-to-Equity | -1.67 | |||||
Debt-to-EBITDA | -0.48 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -0.7 | |||||
3-Year EPS without NRI Growth Rate | 3.3 | |||||
3-Year FCF Growth Rate | -4.2 | |||||
3-Year Book Growth Rate | -60.7 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.15 | |||||
9-Day RSI | 37.82 | |||||
14-Day RSI | 36.13 | |||||
3-1 Month Momentum % | -55.44 | |||||
6-1 Month Momentum % | -17.7 | |||||
12-1 Month Momentum % | -86.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.34 | |||||
Quick Ratio | 0.34 | |||||
Cash Ratio | 0.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19 | |||||
Shareholder Yield % | -127.69 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -136.64 | |||||
ROIC % | -88.13 | |||||
ROC (Joel Greenblatt) % | -14470.38 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -0.25 | |||||
EV-to-EBITDA | -0.26 | |||||
EV-to-FCF | -0.51 | |||||
Earnings Yield (Greenblatt) % | -400 | |||||
FCF Yield % | -1269.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:PTIX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Protagenic Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.449 | ||
| Beta | 1.5224 | ||
| 3-Year Sharpe Ratio | -0.98 | ||
| 3-Year Sortino Ratio | -1.19 | ||
| Volatility % | 117.32 | ||
| 14-Day RSI | 36.13 | ||
| 14-Day ATR ($) | 0.045955 | ||
| 20-Day SMA ($) | 0.217519 | ||
| 12-1 Month Momentum % | -86.66 | ||
| 52-Week Range ($) | 0.1282 - 6.2 | ||
| Shares Outstanding (Mil) | 1.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Protagenic Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Protagenic Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-31 10:00 | In 153 days | ||
| Third quarter earnings results for 2026 | 2026-11-26 | In 117 days | ||
| Second quarter earnings results for 2026 | 2026-09-10 | In 40 days | ||
| First quarter earnings results for 2026 | 2026-08-04 | In 3 days | ||
| Fourth quarter earnings results for 2025 | 2026-03-09 | 0.42 (+0.00%) | ||
| General meeting for 2025 | 2025-12-31 10:00 | 1.36 (-5.56%) | ||
| Third quarter earnings results for 2025 | 2025-11-26 | 2.23 (-5.11%) | ||
| Second quarter earnings results for 2025 | 2025-09-10 | 2.86 (+1.42%) | ||
| First quarter earnings results for 2025 | 2025-05-13 | 3.06 (-3.77%) | ||
| 0.0714286:1 Stock Split | 2025-05-05 | 3.13 (-6.36%) |
Show
Entries
Protagenic Therapeutics Inc Frequently Asked Questions
What is Protagenic Therapeutics Inc(PTIX)'s stock price today?
The current price of PTIX is $0.18. The 52 week high of PTIX is $6.20 and 52 week low is $0.13.
When is next earnings date of Protagenic Therapeutics Inc(PTIX)?
The next earnings date of Protagenic Therapeutics Inc(PTIX) is 2026-08-04 Est..
Does Protagenic Therapeutics Inc(PTIX) pay dividends? If so, how much?
Protagenic Therapeutics Inc(PTIX) does not pay dividend.
Guru Commentaries on OTCPK:PTIX
No articles.
Press Release
Articles on Protagenic Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers